See Today's Golden Star Stocks 🔥 Free for 7 Days See Today's Golden Star Stocks 🔥 Free for 7 Days
NASDAQ:DMAC

Diamedica Therapeutics Stock Predictions

etoro logo Buy DMAC
*Your capital is at risk
$7.49
-0.180 (-2.35%)
At Close: Jul 13, 2026
Forecast Earnings Financials Insider Trading Signals Historical Prices Predictions News Profile
Currently predicting for Tue, 14 Jul 2026
DMAC Live board
Community Bull/Bear
Target Next close

Join the DMAC prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

DMAC Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in
Forecast Desk

3-Month Forecasts For DMAC

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

DMAC Predictions History

Predictor Target Session Target Price Accuracy
Community predictor Next session USD target Record locked
Ranked predictor Previous session Bullish/Bearish Score locked

See the prediction record

Register to view community history, predictor profiles, accuracy, scores, and your own prediction trail for DMAC.

Create free account Log in
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Log in or create a free account to view and request 66-session forecasts for DMAC.
  • Price path
  • Approved predictor
  • 3-month horizon
Create Free Account Log In To View Forecasts
ABOUT DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic ...
Read Full Profile Here
GOLDEN STAR
Ticker Change Signal Date
SRPT
$17.02
10.58% Jun 29
NMRK
$15.02
0.466% Jun 24
X
XMAX
$8.34
2.40% Jun 24
NESR
$25.07
12.49% Jun 23
CAG
$13.43
6.70% Jun 23
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE